Cited by 1,151Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, Jean-Charles, Tan, Daniel S W, Chiari, Rita, Wu, Yi-Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut L, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximillian, Cortot, Alexis B, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario G, McCulloch, Tracey, Sen, Paramita, Dugan, Margaret, Pantano, Serafino, Branle, Fabrice, Massacesi, Cristian, de Castro, Gilberto·2017·The Lancet

DOI 10.1016/s0140-6736(17)30123-x

Open this paper in CoChat — free account

Abstract

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. Methods This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m 2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m 2 ] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening. Investigators and patients were not masked to treatment assignment. The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full analysis set). Efficacy analyses were done based on the full analysis set. All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01828099. Findings Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceriti…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30123-x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citation
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Self-citation
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A., Michellys, P., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 867
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Self-citation

Show all 26 references

Sorted by citations

Items 801–900 of 1,000

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis
Huang, Y., Chu, Q., Wang, J., & Zhang, L. (2025) · Quality of Life Research · doi:10.1007/s11136-025-04088-6 · Cited by 3
Recent Advances in the Biosensors for the Detection of Lung Cancer Biomarkers: A Review
Rahar, P., & Singh, S. (2025) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2025.2606194 · Cited by 3
A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors
Oh, H.-C., Han, Y., Chang, Y., & Kim, H. H. (2026) · Genome biology · doi:10.1186/s13059-026-03977-4 · Cited by 3
2025 Taiwan guidelines on the drug therapy of lung cancer: Advanced non-squamous cell carcinoma with actionable oncogenic drivers
Wu, S.-G., & Chao-Chi, H. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.02.009 · Cited by 3
Management of Metastatic Nonsmall Cell Lung Cancer in Elderly
Sheth, H., Kumar, P., & Limaye, S. A. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1732784 · Cited by 3
Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
Lin, K., Lin, J., Huang, Z., Fu, J., Yi, Q., Cai, J., Khan, M. B., Yuan, Y., & Bu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881493 · Cited by 3
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review
Moinard‐Butot, F., Nannini, S., Fischbach, C., Abdallahoui, S., Demarchi, M., Petit, T., Bender, L., & Schött, R. (2023) · Cancers · doi:10.3390/cancers15204940 · Cited by 3
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis
Filetti, M., Lombardi, P., Falcone, R., Giusti, R., Giannarelli, D., Carcagnì, A., Altamura, V., Scambia, G., & Daniele, G. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00187 · Cited by 3
Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Qin, K., Wang, K., Li, S., Hong, L., Padmakumar, P., Rinsurongkawong, W., Hubert, S. M., Le, X., Vokes, N. I., Rai, K., et al. (2024) · Cancers · doi:10.3390/cancers16050935 · Cited by 4
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
Rathbone, M., O’Hagan, C., Wong, H. H., Khan, A. M., Cook, T., Rose, S., Heseltine, J., & Escriu, C. (2024) · Cancers · doi:10.3390/cancers16071249 · Cited by 3
Correlation between ALK+ non-small cell lung cancer targeted therapy and thrombosis: a systematic review and network meta-analysis
Qi, Y., Wang, X., Guo, T., You, T., & Wang, P. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078173 · Cited by 3
The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment—Literature Review
Gorzelak-Magiera, A., Domagała-Haduch, M., Kabut, J., & Gisterek, I. (2024) · Biomedicines · doi:10.3390/biomedicines12102308 · Cited by 3
Oncogenic ALK fusion in rare subtype of small intestine metastasis from occult lung cancer
Liu, T., Chen, Y., Xu, Z., & Dong, M. (2024) · Lung Cancer Management · doi:10.1080/17581966.2024.2364582 · Cited by 3
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Doi, T., Ishikawa, T., Moriguchi, M., & Itoh, Y. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf012 · Cited by 3
A comprehensive evaluation of ALK inhibitors in the first-line treatment of patients with ALK-positive non-small cell lung cancer
Ye, Z., Zhou, Y., Liu, L., Zhang, Y., Hong, Y., & Rao, Y. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100025 · Cited by 3
Toxicity profiles of ROS1 tyrosine kinase inhibitors in advanced non-small cell lung cancer: a systematic review and proportional meta-analysis
Jiang, B.-X., Zeng, J.-W., Yan, J.-J., & Zhao, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1644034 · Cited by 3
Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib
Hirano, T., Koarai, A., Ichikawa, T., Sato, T., Ohe, T., & Ichinose, M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4913-5 · Cited by 3
Current Landscape of Personalized Therapy
Horn, L., & Cass, A. S. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.011 · Cited by 3
An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer
Schokrpur, S., Hilburn, V., Giustini, N., & Bazhenova, L. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1948014 · Cited by 3
Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients
Gürsoy, P., Çakar, B., Nart, D., & Göker, E. (2021) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_71_20 · Cited by 3
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
Raphael, A., Onn, A., Holtzman, L., Dudnik, J., Urban, D., Kian, W., Cohen, A. Y., Moskovitz, M. T., Zer, A., Bar, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.874712 · Cited by 3
State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain
Steiger, H., Vollmer, K., Rogers, S. J., & Schwyzer, L. (2022) · Neurosurgical Review · doi:10.1007/s10143-022-01839-8 · Cited by 3
Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review
Wu, Y., Lijian, H., Li, W., & Chai, Y. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001432 · Cited by 3
Self-citation
Targeted Therapy for Non–Small Cell Lung Cancer
Brea, E. J., & Rotow, J. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.009 · Cited by 4
Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report
Kato, T., Kunimoto, Y., Kitagawa, M., Asai, Y., Kimyo, T., Nakata, H., Takahashi, M., Chiba, H., Takahashi, H., Miyamoto, A., et al. (2023) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-023-00282-1 · Cited by 3
Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
Yan, L., Zheng, J., Pan, Q., Liang, Y., Yu, P., & Chen, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1264820 · Cited by 3
ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue
Mersiades, A. J., Solomon, B., David, M. T., Lee, C. K., Cummins, M. M., Sebastian, L. T., Ballinger, M. L., Collignon, E., Turnbull, O. M. H., Yip, S., et al. (2023) · Future Oncology · doi:10.2217/fon-2023-0366 · Cited by 4
Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report
Tang, Q., Li, T., Ren, F., Li, X., Cao, W., Yu, H., Mao, F., Cao, C., Zu, L., & Xu, S. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7107 · Cited by 3
A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy
Mesquita, F. P., Lima, L. B., da Silva, E. L., Souza, P. F. N., de Moraes, M. E. A., Burbano, R. M. R., & Montenegro, R. C. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037291318240130103348 · Cited by 3
A novel framework to assess haematology and oncology registration trials: The THEOREMM project
Olivier, T., Haslam, A., Burke, P., Boutron, I., Naudet, F., Ioannidis, J. P. A., & Prasad, V. K. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14267 · Cited by 3
Harnessing CRISPR/Cas9 to overcome targeted therapy resistance in non‑small cell lung cancer: Advances and challenges (Review)
Du, J., Gong, X., Huang, R., Zheng, B., Chen, C., & Zhang, Y. (2025) · Oncology Reports · doi:10.3892/or.2025.8944 · Cited by 5
Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients
Niu, X., Perdomo, S. P., & Blackhall, F. H. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.03.22 · Cited by 3
Neurological Complications of Targeted Therapies
Forst, D. A., & Wen, P. Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-57901-6_16 · Cited by 3
Emerging resistance pathways in lung cancer: what has ROS-1 taught us?
Alrifai, D., Forster, M. D., & Janes, S. M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.11.13 · Cited by 3
The Changing Paradigm of Treatment for Non-Small Cell Lung Cancer Intracranial Metastases
Azzam, G. A., Mellon, E. A., Samuels, S. E., & Yechieli, R. L. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0215-2 · Cited by 3
Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis
Newman, S., Bucknell, N. W., Bressel, M., Tran, P., Campbell, B. A., David, S., Haghighi, N., Hanna, G. G., Kok, D. L., MacManus, M. P., et al. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.10.010 · Cited by 3
Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies
Raffa, E. H., Branson, H. M., Ngan, B., Alexander, S. W., & Abla, O. (2021) · Cancer Reports · doi:10.1002/cnr2.1377 · Cited by 4
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
Moskovitz, M. T., Dudnik, E., Shamai, S., Rottenberg, Y., Popovich-Hadari, N., Wollner, M., Zer, A., Gottfried, M., Mishaeli, M., Rosenberg, S. K., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab005 · Cited by 3
Modern treatment of ALK-positive non-small cell lung cancer
Kharagezov, D. A., Lazutin, Y. N., Арменовна, М. Э., Milakin, A. G., Stateshny, O. N., Leyman, I. A., Gappoeva, M. A., Vitkovskaya, V. N., & Дмитриевич, И. К. (2022) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2022-3-2-5 · Cited by 3
Drug-induced pericarditis
Alusik, S., & Palúch, Z. (2022) · Cor et Vasa · doi:10.33678/cor.2022.047 · Cited by 3
Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States
Hess, L. M., Peterson, P. M., Sugihara, T., Bhandari, N. R., Krein, P. M., & Sireci, A. N. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100761 · Cited by 3
Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review
Zhang, B., Zhang, Y., Xu, J., Zhang, X., Chu, T., Wang, S., Qian, J., Qiao, R., Lü, J., Zhang, L., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0592-z · Cited by 3
First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development
Rocco, D., Gravara, L. D., Battiloro, C., & Gridelli, C. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1600824 · Cited by 3
Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor
Miyoshi, Y., Ogawa, O., Nishida, A., & Masuzawa, M. (2020) · Diabetology International · doi:10.1007/s13340-020-00442-w · Cited by 3
Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis
Choi, W., Lim, H.-J., Park, S.-Y., Han, J., Kim, H. T., Lee, J. S., & Lee, Y. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00733-x · Cited by 3
EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
Matsuda, H., Hara, M., Iwakami, S., & Takahashi, K. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-240295 · Cited by 3
Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib
Wu, Y., Chen, H., Guan, J., Zhang, K., Wu, W., Li, X., & Zhang, J. (2021) · Medicine · doi:10.1097/md.0000000000026449 · Cited by 3
Self-citation
[Recommendations from Experts in the Management of Adverse Reactions to ALK Inhibitors (2021 Version)].
Wang, K., Li, J., Sun, J., Li, L., Zhang, X., Zhang, J., Yu, M., Ye, X., Zhang, M., Zhang, Y., et al. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.32 · Cited by 3
A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases
Muniz, T. P., de Jesus, V. H. F., Sousa, V. A. R., Barbosa, M. V. D. R., & de Lima, V. C. C. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.115 · Cited by 3
The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
Spagnuolo, A., Muto, M., Monaco, F., Colantuoni, G., & Gridelli, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.24 · Cited by 3
Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
Makimoto, G., Ohashi, K., Maeda, Y., & Kiura, K. (2020) · PubMed · doi:10.18926/amo/60796 · Cited by 3
ASCEND-5: too little too late?
Wu, F., & Ou, S. I. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.147 · Cited by 3
J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
Gridelli, C., Casaluce, F., Sgambato, A., Palazzolo, G., & Maione, P. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.76 · Cited by 3
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
Addeo, A., & Metro, G. (2018) · Drugs in Context · doi:10.7573/dic.212537 · Cited by 3
A Retrospective Study of Ensartinib-Treated ALK -Positive Locally Advanced or Metastatic NSCLC Patients in China
Yuan, X., Wang, Y., Yang, M., Wu, P., Chen, H., Yun, Y., Shen, Z., Ji, D., Ma, Y., & Ding, L. (2023) · Lung Cancer Management · doi:10.2217/lmt-2023-0005 · Cited by 2
Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges
Ferreira, C. G., Marchi, P. D., Veloso, G. G. V., Reis, M. X., Barcelos, I. F., & Montella, T. C. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5169 · Cited by 2
Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group
Decoster, L., Camidge, D. R., Fletcher, J. A., Addeo, A., Greystoke, A., Kantilal, K., Bigay-Game, L., Kanesvaran, R., & Gomes, F. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108087 · Cited by 2
Real World Data on the Efficacy of Brigatinib in ALK-Positive Non-Small Cell Lung Cancer: A Single-Center Experience
Krstić, V. Ć., Samardžić, N., Stjepanović, M., Popević, S., Adžić‐Vukičević, T., Glumac, S., Stević, R., Marić, D., Velinović, M., Jovanović, M., et al. (2025) · Cancers · doi:10.3390/cancers17183084 · Cited by 3
Ceritinib–ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models
Tan, S., Yang, Y., Ma, L. M., Zuo, X., Rao, J., Pu, Y., Feng, C., Gu, Z., & Zhang, J. (2025) · Toxicology · doi:10.1016/j.tox.2025.154321 · Cited by 2
Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplification
Guo, S., Li, T., Ge, G., Hu, H., Xue, W.-H., Wang, Y., Zhang, X., Liu, H., Liang, J., Zhang, Y., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109360 · Cited by 2
Update on NSCLC tissue acquisition, processing, and profiling in the molecular age
Conterato, A. J., Belanger, A. R., Yarmus, L. B., & Akulian, J. (2017) · Hematology & Medical Oncology · doi:10.15761/hmo.1000121 · Cited by 2
Complete Metabolic Response in Adenocarcinoma Lung With Lymphangitic Carcinomatosis
Goyal, H., Kishore, S., Ganesan, P., & Halanaik, D. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004463 · Cited by 2
Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor
Ravasio, R., Cranmer, H., Kearns, I., Viti, R., & Corinti, S. (2022) · AboutOpen · doi:10.33393/ao.2022.2450 · Cited by 2
Real‐world treatment and prognostic factors for survival in ALK + non‐small cell lung cancer ( NSCLC ) patients with brain metastases in China
Li, N., Xie, M., Zhou, Z., Sheng, J., Yu, X., & Fan, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14739 · Cited by 2
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
Ma, X., Zhang, K., Xu, J., Gao, H., Yang, S., Qin, H., Wang, H., Gao, F., & Liu, X. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14980 · Cited by 2
Ceritinib inhibits growth and ACTH production of PitNETs: Insights from patient-derived organoids
Yu, H., Zhang, T., Chen, J., Li, X., Zhang, H., Guo, R., Wu, C., Zhang, L., Fan, J., Wang, C., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107993 · Cited by 2
Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment
Tan, L., & Solomon, B. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.08.004 · Cited by 2
Focus on Recommendations for the Management of Non-small Cell Lung Cancer
Lavaud, P., Besse, B., de Baère, T., Deschamps, F., Mussot, S., Pechoux, C. L., Caramella, C., Mercier, O. M., Mezquitta, L., Botticella, A., et al. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02222-9 · Cited by 2
Paradigm shift in the management of metastatic nonsmall cell lung cancer
Gupta, R., Smalley, M., Anusim, N. I., Jindal, V., Rahi, M. S., Gupta, S., Gupta, S. K., & Jaiyesimi, I. A. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14533 · Cited by 3
Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
Fujita, K., Nakayama, M., Sata, M., Nagai, Y., Hisata, S., Mato, N., Suzuki, T., Bando, M., Hizawa, N., & Hagiwara, K. (2021) · Cancer Medicine · doi:10.1002/cam4.4330 · Cited by 2
Clinical data from the real world
Qiu, Z., Xian, X., Liu, C., Yu, M., Lin, F., Huang, M., & Wang, K. (2022) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1453_21 · Cited by 2
Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report
Fang, L., Ding, G., Wang, M., Ye, Y., Yan, X., Ding, P., Wang, J., & Zhang, Y. (2022) · Medicine · doi:10.1097/md.0000000000030255 · Cited by 2
Targeting Oncogenic Driver Mutations in Lung Cancer
Lee, M. H., Rous, F. A., Borczuk, A., Liu, S. V., Gadgeel, S. M., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009336123 · Cited by 2
Emergent radiotherapy for brain and leptomeningeal metastases: a narrative review
Barbour, A. B., Zaki, P. M., McGranahan, T. M., Venur, V. A., Vellayappan, B. A., Palmer, J. D., Halasz, L. M., Yang, J. T., Blau, M., Tseng, Y. D., et al. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1276 · Cited by 2
Spheroids Generated from Malignant Pleural Effusion as a Tool to Predict the Response of Non-Small Cell Lung Cancer to Treatment
Yang, T., Fang, Y., Lin, C.-M., Chen, M., & Lin, C.-L. (2024) · Diagnostics · doi:10.3390/diagnostics14100998 · Cited by 2
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC
Melosky, B. L., Chu, Q. S.-C., Juergens, R. A., Snow, S. L., Blais, N., Cheema, P. K., Sangha, R. S., Agulnik, J. S., Martins, I., Burkes, R. L., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108717 · Cited by 2
Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs
West, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.29 · Cited by 2
ALK Inhibitors in NSCLC- Crizotinib and Beyond
Albaba, H. (2017) · Journal of Cancer Prevention & Current Research · doi:10.15406/jcpcr.2017.08.00275 · Cited by 2
New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey
Berghmans, T., Evison, M., Blum, T. G., Peled, N., & Cadranel, J. L. (2018) · ERJ Open Research · doi:10.1183/23120541.00040-2018 · Cited by 2
Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?
Thai, A. A., & Solomon, B. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy415 · Cited by 2
Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Non–Small Cell Lung Cancer (NSCLC)
Gadgeel, S. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00008-0 · Cited by 2
Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients
Hochmair, M. J., Prosch, H., Krenbek, D., Weinlinger, C., Fabikan, H., & Valipour, A. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000989 · Cited by 2
Self-citation
Tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña : consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO).
Ospina, A. V., Bruges, R. E., Lema, M., Lopes, G. D. L., Jr., Gómez, R., Lombana, M., Vargas, C., Duarte, R., Lobatón, J. F., Yepes, A., et al. (2018) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.364 · Cited by 2
Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study
Yin, Q., Li, P., Wang, P., Zhang, Z., Liu, Q., Sun, Z., Li, W., Ma, L., & Wang, X. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s345439 · Cited by 2
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain
Majem, M., Alvarez, R. M., Granados, A. L. O., de Alda, L. R., Gordo, R., García, J. F., Ivanova-Markova, Y., Domínguez, A. G., Cristóbal, R. S. S., & Rojo, F. (2022) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2022.2449 · Cited by 2
Targeted Therapies in Non-small Cell Lung Cancer
Bauman, J. R., & Edelman, M. J. (2022) · Medical radiology · doi:10.1007/174_2022_312 · Cited by 2
Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer
Rossi, S., Marinello, A., Pagliaro, A., Franceschini, D., Navarria, P., Finocchiaro, G., Toschi, L., Scorsetti, M., & Santoro, A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2162044 · Cited by 3
Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement
Hou, X., Chen, H., Liu, Y., Gong, S.-D., Zhudai, M., & Shen, L. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00537-y · Cited by 2
Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
Figueiredo, A. A., Rodrigues, A., Gaspar, C., & Felizardo, M. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00393-z · Cited by 2
ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards
Bestvina, C. M., & Vokes, E. E. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30708-8 · Cited by 2
Gene Fusion in NSCLC
Palmirotta, R., Quaresmini, D., Lovero, D., Mannavola, F., Dammacco, F., & Silvestris, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00031-4 · Cited by 2
Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer
Miao, E., Seetharamu, N., Sullivan, K. M., Eng, S., & Lee, C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019840596 · Cited by 2
Twenty‐five years of Respirology: Advances in lung cancer
Ang, M., & Mok, T. S. K. (2019) · Respirology · doi:10.1111/resp.13745 · Cited by 2
[Targeted Therapies for Driver Gene Mutation-positive Lung Cancer Patients with Brain Metastasis].
Li, W., Bai, R., & Cui, J. (2019) · PubMed · doi:10.3779/j.issn.1009-3419.2019.11.06 · Cited by 2
[Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer].
Tian, Y., Tian, T., Yu, P., Ren, L., Gong, Y., Yao, W., Zhang, X., Yin, J., He, L. C., Chen, L., et al. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.102.33 · Cited by 2
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
Mogenet, A., Greillier, L., & Tomasini, P. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s267437 · Cited by 2
Immunotherapy related pericardial effusion on chest CT
Capaccione, K. M., Huang, S., Toor, Z., May, B. L., Deng, A., & Salvatore, M. M. (2021) · Clinical Imaging · doi:10.1016/j.clinimag.2021.11.029 · Cited by 2
An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC)
Sharp, J., & Prasad, V. K. (2022) · BMC Cancer · doi:10.1186/s12885-022-09179-y · Cited by 2
Multiple cardiotoxicities during osimertinib therapy
Kobat, H., Davidson, M., Elkonaissi, I., Foreman, E., & Nabhani‐Gebara, S. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231164301 · Cited by 2
TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
Qin, J., Li, R., Ma, H., Ding, P., Yang, Q., Hu, L., Wu, D., & Xiong, S. (2023) · Medicine · doi:10.1097/md.0000000000034138 · Cited by 2

Authors: Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., Hochmair, M., Cortot, A. B., Tsai, C.-M., Moro-Sibilot, D., Campelo, R. G., McCulloch, T., Sen, P., Dugan, M., Pantano, S., Branle, F., Massacesi, C., & de Castro, G.
Affiliations: Université Paris-Sud (FR)
National Cancer Centre Singapore (SG)
Azienda Ospedaliera di Perugia (IT)
Guangdong General Hospital (CN)
Universidad Complutense de Madrid (ES)
University Hospital Cologne (DE)
Songklanagarind Hospital (TH)
Azienda Ospedaliera San Gerardo (IT)
National Taiwan University Hospital (TW)
Otto Wagner Hospital (AT)
Centre Hospitalier Universitaire de Lille (FR)
Taipei Veterans General Hospital (TW)
Universidade da Coruña (ES)
Novartis (Switzerland) (CH)
Corresponding author: Soria, Jean-Charles
ORCID: Soria, Jean-Charles
Tan, Daniel S W
Chiari, Rita
Wu, Yi-Long
Paz-Ares, Luis
Geater, Sarayut L
Cortinovis, Diego
Yu, Chong-Jen
Hochmair, Maximillian
Cortot, Alexis B
Tsai, Chun-Ming
Campelo, Rosario G
Branle, Fabrice
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-03
Volume: 389
Issue: 10072
Pages: 917-929
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30123-x
OpenAlex: W2581996620
Cited by: 1,151
References: 26
Citations by year: 2026: 38 · 2025: 73 · 2024: 98 · 2023: 123 · 2022: 142 · 2021: 128 · 2020: 139 · 2019: 146 · 2018: 168 · 2017: 94
FWCI: 123.94
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ceritinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, first-line therapy, platinum-based chemotherapy, pemetrexed, progression-free survival, targeted therapy, adverse events, diarrhea, elevated liver enzymes, brain metastases, treatment safety and efficacy comparison, WHO performance status
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Sulfones, Carboplatin, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks